Brexit

The United Kingdom (UK) formally left the European Union (EU) on the 31st January 2020 and became a third country to the EU. The Brexit transition period began on the 1st February 2020 and ended on the 31st December 2020.  

 

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is now the stand-alone medicines and medical devices regulator for the UK.

The Northern Ireland (NI) Protocol became applicable on 1st January 2021, and was designed as a practical solution to avoid a hard border on the island of Ireland, whilst ensuring that the UK, including NI, could leave the EU as a whole.  The initial period of application of the protocol is four years.

 

In accordance with the protocol, NI align with all relevant EU rules relating to the placing on the market of manufactured goods. As such, NI is assimilated to a Member State.  BlueReg can help navigate you through the implications for this, with respect to medicinal products.

 

BlueReg experts can assist with all aspects of MHRA Brexit related guidance and activities, including the new routes for obtaining a Marketing Authorisation (MA), clinical trials, paediatrics, pharmacovigilance, orphan drugs and life cycle maintenance.

 

BlueReg can also guide you through the requirements for products approved via the Centralised Procedure (CP), Decentralised Procedure (DCP) and Mutual Recognition Procedure (MRP) and the steps that are required as a consequence of Brexit.

Associated services

BlueReg assists companies to plan and submit any necessary changes to existing marketing authorizations before the end of the Brexit transition period in order to comply with EU law. Please contact us or follow our BlueReg Linkedin page to be kept up to date with the Medicines and Healthcare products Regulatory Agency (MHRA) Brexit guidance as they are issued.

Associated services

BlueReg assists companies to plan and submit any necessary changes to existing marketing authorizations before the end of the Brexit transition period in order to comply with EU law. Please contact us or follow our BlueReg Linkedin page to be kept up to date with the Medicines and Healthcare products Regulatory Agency (MHRA) Brexit guidance as they are issued.

Associated services

BlueReg assists companies to plan and submit any necessary changes to existing marketing authorizations before the end of the Brexit transition period in order to comply with EU law. Please contact us or follow our BlueReg Linkedin page to be kept up to date with the Medicines and Healthcare products Regulatory Agency (MHRA) Brexit guidance as they are issued.

Associated services

BlueReg assists companies to plan and submit any necessary changes to existing marketing authorizations before the end of the Brexit transition period in order to comply with EU law. Please contact us or follow our BlueReg Linkedin page to be kept up to date with the Medicines and Healthcare products Regulatory Agency (MHRA) Brexit guidance as they are issued.

Associated news

UK Medicines and Medical Devices Bill begins passage through Parliament

The purpose of the Bill is to replace the EU Human Medicines Directive, which will...

Learn more

EMA GUIDANCE – COVID-19

Given the support given to our clients in interactions with health authorities all around the...

Learn more

UK BREXIT – eCTD BASELINE for Converting CAPs into UK MAs

From 1 January 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) will be the UK’s stand-alone...

Learn more


Line - Organism